
Lice Treatment Market - By Product Type (OTC [Permethrin, Pyrethrin], Prescription [Ivermectin, Spinosad, Malathion]), Type (Branded, Generic), Route of Administration, Condition, Dosage Form, Distribution Channel - Global Forecast (2024 - 2032)
Description
Lice Treatment Market - By Product Type (OTC [Permethrin, Pyrethrin], Prescription [Ivermectin, Spinosad, Malathion]), Type (Branded, Generic), Route of Administration, Condition, Dosage Form, Distribution Channel - Global Forecast (2024 - 2032)
Global Lice Treatment Market will record over 6.5% CAGR from 2024 to 2032, ushered by increased healthcare expenses and rising disposable incomes. The Bureau of Economic Analysis reported a 4.2% growth in disposable income in the U.S. economy for the 12 months ending in the last quarter of 2023. Over the year, per capita income rose from 57,386 at the end of 2022 to 61,084 at the end of 2023.
As healthcare spending amplifies, consumers are more willing to invest in effective solutions for managing lice infestations. This trend is particularly pronounced in regions where access to healthcare services and disposable income levels have improved, fostering demand for traditional as well as innovative treatment alternatives.
Heightened awareness and evolving regulatory landscapes propel the market expansion, ensuring that treatments meet strict standards while catering to diverse consumer preferences. These factors collectively contribute to the sustained growth of the lice treatment industry globally.
The overall lice treatment market is classified based on product type, type, route of administration, condition, dosage form, distribution channel, and region.
The prescription medications segment will register an impressive CAGR between 2024 and 2032. Prescription medications often offer stronger formulations that can effectively eradicate resistant lice strains, addressing growing concerns over treatment efficacy. Additionally, healthcare professionals increasingly prescribe these medications, emphasizing their role in managing severe infestations or cases where over-the-counter remedies have proven inadequate. Moreover, prescription treatments are perceived as more reliable and are preferred by individuals seeking quicker and more comprehensive solutions to lice infestations, boosting demand within this specialized segment of the market.
By 2032, the branded sector will hold a substantial lice treatment market share. Branded treatments often carry established reputations for efficacy and safety, which instill consumer confidence. Their marketing efforts and visibility in pharmacies and online platforms also contribute to increased consumer awareness and preference. Furthermore, branded treatments frequently offer additional benefits. such as user-friendly formulations or added features that appeal to specific consumer needs, further driving their popularity. The branded segment continues to expand as consumers prioritize trusted solutions and convenient options for managing lice infestations effectively.
During the forecast period, the Europe lice treatment market will showcase a robust CAGR. Increased migration and travel contribute to the spread of lice infestations, prompting higher demand for effective treatments. Moreover, stringent hygiene standards in schools and workplaces necessitate quick and reliable solutions, catapulting the market growth. Additionally, rising healthcare expenditures across European countries enable greater access to a variety of treatment options, including both prescription and over-the-counter remedies. These factors, coupled with a growing awareness of personal hygiene and health, propel the expansion of the lice treatment industry in Europe.
Table of Contents
140 Pages
- Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
- Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
- Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of lice infestations
- 3.2.1.2 Easy availability of lice treatment products
- 3.2.1.3 Preference for natural and non-toxic products
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Lack of awareness
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
- Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
- Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Million)
- 5.1 Key trends
- 5.2 OTC products
- 5.2.1 Permethrin
- 5.2.2 Pyrethrin
- 5.2.3 Other OTC products
- 5.3 Prescription medications
- 5.3.1 Ivermectin
- 5.3.2 Spinosad
- 5.3.3 Malathion
- 5.3.4 Other prescription medications
- Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)
- 6.1 Key trends
- 6.2 Branded
- 6.3 Generic
- Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Topical
- Chapter 8 Market Estimates and Forecast, By Condition, 2021 - 2032 ($ Million)
- 8.1 Key trends
- 8.2 Pediculosis capitis
- 8.3 Pediculosis corporis
- 8.4 Pediculosis pubis
- Chapter 9 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)
- 9.1 Key trends
- 9.2 Tablets
- 9.3 Shampoos
- 9.4 Lotions
- 9.5 Cream
- 9.6 Other dosage forms
- Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)
- 10.1 Key trends
- 10.2 Hospital pharmacies
- 10.3 Retail pharmacies
- 10.4 Other distribution channels
- Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 11.1 Key trends
- 11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 Rest of Asia Pacific
- 11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
- 11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 Rest of Middle East and Africa
- Chapter 12 Company Profiles
- 12.1 Alliance Pharma PLC
- 12.2 Azurity Pharmaceuticals, Inc.
- 12.3 Fleming Medical Ltd.
- 12.4 Oystershell Consumer Health
- 12.5 Parapro Pharmaceuticals
- 12.6 Perrigo Company plc
- 12.7 Prestige Consumer Healthcare Inc.
- 12.8 Reckitt Benckiser Group plc
- 12.9 Sanofi S.A.
- 12.10 Thornton & Ross Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.